Literature DB >> 3600293

Naloxone decreases the inhibiting effect of ethanol on the release of arginine-vasopressin induced by cigarette smoking in man.

P Chiodera, L d'Amato, C Davoli, R Volpi, R Delsignore, A Gnudi, V Coiro.   

Abstract

In order to establish whether ethanol exerts its inhibiting effect on the nicotine-induced release of arginine-vasopressin (AVP) by interacting with an opioid pathway, six normal volunteers were treated with naloxone (2 or 4 mg as IV bolus, plus 5 or 10 mg infused over 105 minutes) during (2 nonfilter) cigarette smoking and ethanol (50 mL to 110 mL of whiskey) drinking. In addition, control experiments with naloxone, ethanol, or cigarette smoking alone were performed. When given alone, naloxone and ethanol did not modify AVP secretion, whereas nicotine increased plasma AVP levels by about 2.5-fold. This effect was completely blocked by ethanol. In the presence of naloxone, AVP rose only by about 1.7-fold in response to nicotine. Since naloxone only partially reversed the inhibiting effects of ethanol, only a partial involvement of opioid peptides in ethanol action might be supposed. Alternatively, ethanol and naloxone-sensitive opioids might produce their inhibiting effects on AVP rise in response to nicotine through independent pathways.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3600293     DOI: 10.1016/0026-0495(87)90121-1

Source DB:  PubMed          Journal:  Metabolism        ISSN: 0026-0495            Impact factor:   8.694


  2 in total

1.  Increase by naloxone of arginine vasopressin and oxytocin responses to insulin-induced hypoglycemia in obese men.

Authors:  V Coiro; L Capretti; G Speroni; A Castelli; L Bianconi; U Cavazzini; A Marcato; R Volpi; P Chiodera
Journal:  J Endocrinol Invest       Date:  1990-10       Impact factor: 4.256

2.  Naloxone decreases the inhibitory effect of ethanol on the release of arginine-vasopressin induced by physical exercise in man.

Authors:  Vittorio Coiro; A Casti; E Volta; A Melani; M L Maffei; P Rubino; P Vacca; G Saccani-Jotti; R Volpi; P Chiodera
Journal:  J Neural Transm (Vienna)       Date:  2009-08-01       Impact factor: 3.575

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.